-
Mashup Score: 0
Alicia Morgans speaks with Jonathan Rosenberg about the approval of the combination of Enfortumab vedotin (EV) and Pembrolizumab for urothelial carcinoma treatment. Dr. Rosenberg notes the impressive response rates (64.5%) from the combination, as compared to EV monotherapy (45%), and highlights the promising survival rates, which significantly exceed expectations for a cisplatin-eligible…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 0
Alicia Morgans speaks with Jonathan Rosenberg about the approval of the combination of Enfortumab vedotin (EV) and Pembrolizumab for urothelial carcinoma treatment. Dr. Rosenberg notes the impressive response rates (64.5%) from the combination, as compared to EV monotherapy (45%), and highlights the promising survival rates, which significantly exceed expectations for a cisplatin-eligible…
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
A breakthrough in #urothelial cancer treatment: enfortumab vedotin combination therapy - expert insights and impressive response rates. @DrRosenbergMSK @MSKCancerCenter and @CaPsurvivorship @DanaFarber discuss on UroToday > https://t.co/E8a2is197W https://t.co/Fu3YQHkB7d
-
-
Mashup Score: 0Matthew Galsky on Olaparib in Advanced Bladder Cancer Harboring DDR Gene Alterations - 7 month(s) ago
Studies across a range of solid tumor types, including breast, ovarian, and pancreatic cancers, have demonstrated clinical benefit with poly (ADP-ribose) polymerase (PARP) inhibition, particularly in patients harboring alterations in DNA damage response (DDR) genes such as BRCA1/2. A growing body of evidence also suggests that PARP inhibition may be effective in a broader range of DDR alterations.
Source: www.medpagetoday.comCategories: General Medicine News, Latest HeadlinesTweet-
What do you consider the most likely explanation for the modest activity of polymerase inhibition in metastatic #urothelial cancer and why? #Bladder #oncology @ASCO #ASCOReadingRoom Read more: https://t.co/VMHmhtHAsU https://t.co/D6TjmlhNOB
-
-
Mashup Score: 0
Alicia Morgans speaks with Jonathan Rosenberg about the approval of the combination of Enfortumab vedotin (EV) and Pembrolizumab for urothelial carcinoma treatment. Dr. Rosenberg notes the impressive response rates (64.5%) from the combination, as compared to EV monotherapy (45%), and highlights the promising survival rates, which significantly exceed expectations for a cisplatin-eligible…
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
A breakthrough in #urothelial cancer treatment: enfortumab vedotin combination therapy - expert insights and impressive response rates. @DrRosenbergMSK @MSKCancerCenter and @CaPsurvivorship @DanaFarber discuss on UroToday > https://t.co/E8a2is197W https://t.co/jOELarfe5F
-
-
Mashup Score: 0A Breakthrough in Urothelial Cancer Treatment: Enfortumab Vedotin Combination Therapy - Expert Insights and Impressive Response Rates - Jonathan E. Rosenberg - 10 month(s) ago
Alicia Morgans speaks with Jonathan Rosenberg about the approval of the combination of Enfortumab vedotin (EV) and Pembrolizumab for urothelial carcinoma treatment. Dr. Rosenberg notes the impressive response rates (64.5%) from the combination, as compared to EV monotherapy (45%), and highlights the promising survival rates, which significantly exceed expectations for a cisplatin-eligible…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
A breakthrough in #urothelial cancer treatment: enfortumab vedotin combination therapy - expert insights and impressive response rates. @DrRosenbergMSK @MSKCancerCenter and @CaPsurvivorship @DanaFarber discuss on UroToday > https://t.co/E8a2is197W https://t.co/zvenIMKb5C
-
-
Mashup Score: 0Derk C.F. Klatte, MD, on the Benefits of Pancreatic Cancer Surveillance - 11 month(s) ago
Detected early disease in a high-risk cohort, ‘substantially’ improving survival
Source: www.medpagetoday.comCategories: General Medicine News, Latest HeadlinesTweet-
There are only two other previous prospective trials of perioperative #chemotherapy for upper-tract #urothelial carcinoma. How does your trial compare with those? #oncology @ASCO #ASCOReadingRoom https://t.co/UMbANdopd6 https://t.co/W5Hjaagsz8
-
-
Mashup Score: 0Wolters Kluwer Health - 11 month(s) ago
JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable JavaScript Firefox From the Tools…
Source: lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#Urothelial cancer treatments are subject to factors such as tumor type and stage. Clarifying the molecular landscape can help distinguish specific subtypes and help develop targeted therapy. @BladderCancerUS https://t.co/HsNjLJQSiS https://t.co/3cyfsatAmp
-
-
Mashup Score: 0Wolters Kluwer Health - 12 month(s) ago
JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable JavaScript Firefox From the Tools…
Source: lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The @US_FDA recently granted accelerated approval to enfortumab vedotin-ejfv with pembrolizumab for patients with locally advanced or metastatic #urothelial carcinoma who are ineligible for cisplatin-containing chemotherapy. https://t.co/TVoscIlLy7 https://t.co/kgL13b6YbQ
-
-
Mashup Score: 0Wolters Kluwer Health - 12 month(s) ago
JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable JavaScript Firefox From the Tools…
Source: lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#Urothelial cancer treatments are subject to factors such as tumor type and stage. Clarifying the molecular landscape can help distinguish specific subtypes and help develop targeted therapy. @BladderCancerUS https://t.co/HsNjLJQSiS https://t.co/wRxY7qZTVx
-
-
Mashup Score: 0AUA 2023: Diagnostic Accuracy of Oncuria-Detect in the Detection of Upper Tract Urothelial Tumors - 12 month(s) ago
AUA 2023, upper tract urothelial cancers (UTUC), urine cytology, Oncuria, angiogenin (ANG), apolipoprotein E (APOE), alpha-1 antitrypsin (A1AT), carbonic anhydrase 9 (CA9), interleukin-8 (IL-8), matrix metallopeptidase 9 (MMP9), matrix metallopeptidase 10 (MMP10), plasminogen activator inhibitor 1 (PAI1), syndecan 1 (SDC1), and vascular endothelial growth factor (VEGF).
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
Diagnostic accuracy of Oncuria-Detect in the detection of upper tract #Urothelial tumors. Presentation by Hideki Furuya, MD @CedarsSinai. #AUA23 written coverage by @RuchikaTalwarMD @VUMCurology > https://t.co/MTcEluyrj1 @AmerUrological https://t.co/MkZCvHxDGM
-
A breakthrough in #urothelial cancer treatment: enfortumab vedotin combination therapy - expert insights and impressive response rates. @DrRosenbergMSK @MSKCancerCenter and @CaPsurvivorship @DanaFarber discuss on UroToday > https://t.co/E8a2is197W https://t.co/jOELarfe5F